EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cracking PRMT5: Mechanistic insights, clinical advances, and AI-driven strategies

Faranak Alipourgivi, Jing Su, Tao Lu

Cancer Letters · 2025-12 · 634 · 218075

DOI: 10.1016/j.canlet.2025.218075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025-12. Verfasst von Faranak Alipourgivi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Molecular Biology and Pharmacology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA; Melvin and Bren …. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Artificial Intelligence, Neoplasms, Enzyme Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein arginine methyltransferase 5 (PRMT5) is a type II methyltransferase that catalyzes symmetric arginine dimethylation on histone and non-histone proteins, thereby modulating transcription, RNA splicing, and diverse signaling pathways. Dysregulated PRMT5 activity contributes to tumorigenesis and multiple pathological conditions, positioning it as a high-priority therapeutic target with strong translational relevance. Current inhibitor strategies encompass S-adenosylmethionine (SAM)-competitive agents, substrate-competitive and substrate-dependent modulators, dual-binding and methylthioadenosine (MTA)-cooperative inhibitors, PROTAC-based degraders, repurposed FDA-approved drugs, and rational combination regimens designed to improve efficacy or overcome resistance. These approaches differ in mechanism of action, tumor specificity, and toxicity profiles. This review highlights their mechanistic underpinnings, clinical development, and inherent limitations, while also examining the potential application of PRMT5 inhibitors in non-oncologic indications, including ocular and cardiovascular diseases. Finally, it explores the role of biomedical informatics and artificial intelligence (AI) in drug repurposing and outlines future directions for advancing PRMT5-targeted therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesArtificial IntelligenceNeoplasmsEnzyme InhibitorsHumansDrug RepositioningAnimals

Stichwörter der Autor:innen

Arginine methylationArtificial intelligenceClinical trialDrugPRMT5

Substanzen

Protein-Arginine N-MethyltransferasesPRMT5 protein, humanEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Biochemistry, Molecular Biology and Pharmacology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medici…
  • Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • NIGMS NIH HHS
  • V Foundation
  • Ralph W and Grace M Showalter Research Trust Fund
  • National Institute of General Medical Sciences
  • National Center for Advancing Translational Sciences
  • Kay Yow Cancer Fund

Zitieren

APA

Alipourgivi, F., Su, J., & Lu, T. (2025). Cracking PRMT5: Mechanistic insights, clinical advances, and AI-driven strategies. Cancer Letters, 634, 218075. https://doi.org/10.1016/j.canlet.2025.218075

Vancouver

Alipourgivi F, Su J, Lu T. Cracking PRMT5: Mechanistic insights, clinical advances, and AI-driven strategies. Cancer Letters. 2025;634:218075. doi:10.1016/j.canlet.2025.218075

BibTeX
@article{Alipourgivi2025,
  author = {Alipourgivi, Faranak and Su, Jing and Lu, Tao},
  title = {Cracking PRMT5: Mechanistic insights, clinical advances, and AI-driven strategies},
  journal = {Cancer Letters},
  year = {2025},
  volume = {634},
  pages = {218075},
  doi = {10.1016/j.canlet.2025.218075}
}
Kostenlos starten →